
Bellevue Entrepreneur Switzerland (CH)
ISIN-No.: CH0023244368
YTD: 9.02%
Active share: 48.28
Anzahl Positionen: 41
Explained in 90 seconds
Owner-operated or family-run companies think in generations, not in quarters
Solid balance sheets, high innovative strength and safety awareness have a positive effect on the share price
Companies impress with high ESG scores
Indexed performance (as at: 14.05.2025)
NAV: CHF 311.91 (13.05.2025)
Rolling performance (14.05.2025)
A-CHF | Benchmark | |
13.05.2024 - 13.05.2025 | 4.93% | 5.81% |
13.05.2023 - 13.05.2024 | -0.92% | -0.10% |
13.05.2022 - 13.05.2023 | 5.91% | 3.16% |
12.05.2021 - 13.05.2022 | -6.03% | 5.94% |
Annualized performance (14.05.2025)
A-CHF | Benchmark | |
1 year | 4.93% | 5.81% |
3 years | 3.26% | 2.46% |
5 years | 8.02% | 6.06% |
10 years | 7.02% | 5.76% |
Since Inception p.a. | 6.52% | 5.13% |
Cumulative performance (14.05.2025)
A-CHF | Benchmark | |
1M | 16.33% | 14.04% |
YTD | 9.02% | 7.83% |
1 year | 4.93% | 5.81% |
3 years | 10.11% | 7.58% |
5 years | 47.07% | 34.22% |
10 years | 97.01% | 75.03% |
Since Inception | 234.52% | 160.37% |
Annual performance
A-CHF | Benchmark | |
2024 | 1.38% | 3.83% |
2023 | 8.21% | 6.53% |
2022 | -24.92% | -17.83% |
2021 | 26.24% | 23.38% |
Facts & Key figures
Investment Focus
The fund actively invests in listed owner-managed companies in Switzerland where an entrepreneur or a founder family holds at least a 20% of a company’s voting rights. The qualities of these companies – a focused business model, Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
Investment Manager | Bellevue Asset Management AG |
Custodian | CACEIS Bank, Montrouge, Zurich Branch |
Fund Administrator | CACEIS Bank, Montrouge, Zurich Branch |
Auditor | PriceWaterhouseCoopers |
Launch date | 04.04.2006 |
Year end closing | 31. Dec |
NAV Calculation | Daily "Forward Pricing" |
Cut of time | 15:00 CET |
Management Fee | 1.25% |
Subscription Fee (max.) | 5.00% |
ISIN number | CH0023244368 |
Valor number | 2324436 |
Bloomberg | SWENTEQ SW |
Legal Information
Legal form | Investment funds under Swiss law |
SFDR category | Article 8 |
Key data (30.04.2025, base currency CHF)
Beta | 1.01 |
Volatility | 15.00 |
Tracking error | 3.62 |
Active share | 48.28 |
Correlation | 0.97 |
Sharpe ratio | -0.02 |
Information ratio | -0.16 |
Jensen's alpha | -0.59 |
No. of positions | 41 |
Portfolio
Top 10 positions
Market capitalization
Breakdown by sector
Benefits & Risks
Benefits
- Above-average top line growth driven by high innovation and strong pricing power.
- Higher operating margins on the back of high market share ("Champion in the niche") combined with good cost discipline.
- More conservatively financed, lower debt exposure and a higher risk capacity compared to non-family businesses.
- Multi-award-winning management team with a long and successful track record investing in owner-run firms.
- Entrepreneurs for entrepreneurs – the Bellevue Group is itself an owner-run company with the majority of shares held by employees.
Risks
- The fund actively invests in equities. Equities are subject to price fluctuations and so are also exposed to the risk of price losses.
- Shares in smaller businesses are generally traded in lower volumes and are subject to bigger price fluctuations than larger enterprises.
- The fund may invest a proportion of its assets in financial instruments that might under certain circumstances have a relatively low level of liquidity, which can in turn affect the fund’s liquidity.
- Succession planning poses an additional risk for owner-run companies.
- The fund may engage in derivatives transactions. The increased opportunities gained come with an increased risk of losses.
Review / Outlook
Against this backdrop, the fund rose 0.8%, 35 bps better versus the SPIEX benchmark.
Main detractors in the month were Roche (-6.1%), Kardex (-8.7%) and Straumann (-4.1%). The healthcare space was not immune to the sweeping tariff announcements and the subsequent USD weakness. Roche’s Q1 results reflected solid overall sales performance overshadowed by FX cuts to FY 2025 guidance. Kardex published strong 2H24 results early March with a clear beat at all levels. The market was surprised by the announcement of a large investment plan over the next two years for future growth, with negative effect on ST margins. Straumann reported ok-ish Q1results with some persistent weakness in the US, while other regions including China displayed good growth. We stay underweight as we deem the valuation excessive in light of the challenging market environment.
Main contributors in the month were Belimo (+29%), Swissquote (+12.1%) and Compagnie Financière Tradition (+7.4%). Belimo surprised the markets with a positive profit warning on the back of their strong US DC business. Introducing Q1 key figures as a premiere, Belimo upped the FY 2025 guidance to 15-20% top line growth and EBIT margins in excess of 20%. Swissquote rebounded after releasing FY24 results and 2025 guidance end of March. The business model remains resilient and well diversified, fully unscathed by the tariff problematic, which is attractive in the current environment. The management is as always conservative in its forward guidance and we see Swissquote’s crypto exposure as a welcome revenue hedge. The inter-dealer broker Compagnie Financière Tradition reported revenue growth of 13.5% for Q1, continuing its growth trajectory. The quarterly comment summarizes the qualities of the business model very well: "This performance was achieved in a market environment characterized by a cautious approach from major central banks in response to mixed economic signals, amid ongoing geopolitical tensions and increased volatility, which benefited the Group's activities".
Dokumente
Show moreShow less